| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC3144 | Lsn3172176 Precursor | Precursor for 11C-radiolabelling LSN3172176 PET scan |
|
| DCC3145 | Lsn335984 Trihydrochloride | Selective inhibitor of P-glycoproteins (P-gp) |
|
| DCC3146 | Lspn451 | Novel potent xanthine oxidase inhibitor |
|
| DCC3147 | Lt-106-175 | Novel potent inhibitor of FLT3 mutations, also inhibiting CDK2 and CDK6 |
|
| DCC3148 | Ethyl-3,4-dephostatin | Novel inhibitor of the interactions of CFTR-associated ligand (CAL) and PSD-95/Dlg1/ZO-1 (PDZ) domain |
|
| DCC3149 | L-threonyl-l-threonine | Peptide metabolite |
|
| DCC3150 | Lturm-36 | Novel PI 3-kinase delta inhibitor |
|
| DCC3151 | Lu Aa27122 | Brain penetrant high affinity α1A-adrenoceptor ligand |
|
| DCC3152 | Lu Aa41063 | Novel potent and selective hA2A receptor antagonist |
|
| DCC3153 | Lu Af58786 | Novel potent and selective inhibitor of LRRK2, inhibiting LRRK2 WT, the overactive variant G2019S, and the resistant mutant A2016T56 at 12 nM, 19 nM and 93 nM, respectively |
|
| DCC3154 | Lu Af58801 | Novel, potent, selective and brain penetrant positive allosteric modulator of alpha-7 nicotinic acetylcholine receptors |
|
| DCC3155 | Lu-001i | Novel potent and selective LMP2 inhibitor, also inhibiting mouse 20S proteasomes |
|
| DCC3156 | Lu-002 | Novel β2-specific inhibitor, potently targeting both β2c and β2i, displaying moderate trypanocidal activity |
|
| DCC3157 | Lu-002c | Novel potent β2c-specific inhibitor, displaying moderate trypanocidal activity |
|
| DCC3158 | Lu-002i | Novel β2i-specific inhibitor, displaying moderate trypanocidal activity |
|
| DCC3159 | Lu-aa47070 | Potent and selective adenosine A2A receptor antagonist |
|
| DCC3160 | Lu-af11205 | Potent mGlu5 receptor positive allosteric modulator (PAM) |
|
| DCC3161 | Luf-5764 | A1 adenosine receptor antagonist |
|
| DCC3162 | Luf-6056 | Human adenosine A1 receptor antagonist |
|
| DCC3163 | Luf-6258 | Hybrid ortho/allosteric ligand of the adenosine A(1) receptor |
|
| DCC3164 | Lugdunin | Thiazolidine-containing cyclic peptide antibiotic, suppressing growth of species of disease-causing bacteria in that part of the human microbiome |
|
| DCC3165 | Luminespib Mesylate | Novel inhibitor of heat shock protein 90 (Hsp90) |
|
| DCC3166 | Luminolate (luminol Sodium Salt) | Immune modulator with SARS-CoV-2 antiviral activity via a multi-target mechanism including localized, self-limiting reactive oxygen species (ROS) scavenging activities that were demonstrated in a model of lipopolysaccharide (LPS)-induced joint inflammatio |
|
| DCC3167 | Lx7101 Hydrochloride | Novel Dual LIM-Kinase and ROCK Inhibitor for the Treatment of Glaucoma |
|
| DCC3168 | lxrβ-agonist-19 | Novel selective LXRβ agonist, reducing total brain Aβ |
|
| DCC3169 | Lxy6006 | Novel Manassantin A Derivative, Inhibiting Hypoxia-Inducible Factor 1 and Tumor Growth |
|
| DCC3170 | Lxy6090 | Novel potent HIF-1 inhibitor, also downregulating the protein level of HIF-1alpha, which depended on von Hippel-Lindau for proteasome degradation, showing in vivo anticancer efficacy by decreasing the HIF-1alpha expression in nude mice bearing MX-1 tumor |
|
| DCC3171 | Ly2019-005 | Novel LRRK2 kinase inhibitor against the wild-type and G2019S mutant LRRK2 kinase being 424.40 ± 1.31 nM, 378.80 ± 1.20 nM, respectively |
|
| DCC3172 | Ly2019-006 | Novel LRRK2 kinase inhibitor against the wild-type and G2019S mutant LRRK2 kinase being 1526.00 ± 0.87 nM, 1165.00 ± 1.18 nM, respectively |
|
| DCC3173 | Ly2048978 | Novel, potent, orally-bioavailable kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders |
|
